Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapy
Journal of Gynecologic Oncology · 2024
DOI: 10.3802/jgo.2024.35.e73 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2024. Verfasst von Young Joo Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Bevacizumab, Mutation, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
OBJECTIVE: We aimed to revalidate the chemotherapy response score (CRS) system as a prognostic factor for ovarian cancer patients with breast cancer gene (BRCA) mutations or those receiving frontline poly-ADP ribose polymerase (PARP) inhibitors or bevacizumab as maintenance therapy. METHODS: A retrospective analysis was performed using medical records of patients with high-grade serous carcinoma who received neoadjuvant chemotherapy followed by interval debulking surgery between January 2007 and December 2021 at 5 tertiary medical institutions in South Korea. At each hospital, pathologists independently assessed each slide of omental tissues obtained from surgery using the CRS system. Progression-free survival (PFS) and overall survival (OS) values were obtained using Kaplan-Meier analysis to evaluate the effect of BRCA mutation, maintenance therapy, and CRS on survival time. RESULTS: Of 466 patients, BRCA mutations were detected in 156 (33.5%) and 131 (28.1%) were treated with maintenance therapy; 98 (21.0%) and 42 (9.0%) were treated with PARP inhibitors or bevacizumab, respectively. Patients with CRS3 had significantly longer PFS than those with CRS1 or 2 (24.7 vs. 16.8 months, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea.
- Department of Obstetrics and Gynecology, Asan Medical Center, Ulsan University Medical School, Seoul, Korea.
- Department of Obstetrics and Gynecology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.
- Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
- Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea. jungyunlee@yuhs.ac.
ORCID-Profile: Young Joo Lee, Yoon Kyung Shin, Nae Ry Kim, Se Ik Kim, Yoo-Young Lee, Jeong-Yeol Park, Jae-Weon Kim, Hyun-Woong Cho, Jung-Yun Lee
Zitieren
APA
Lee, Y. J., Shin, Y. K., Kim, N. R., Kim, S. I., Lee, Y. Y., Park, J. Y., Kim, J. W., Cho, H. W., & Lee, J. Y. (2024). Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapy. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2024.35.e73
Vancouver
Lee YJ, Shin YK, Kim NR, Kim SI, Lee YY, Park JY, et al. Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapy. Journal of Gynecologic Oncology. 2024. doi:10.3802/jgo.2024.35.e73
BibTeX
@article{Lee2024,
author = {Lee, Young Joo and Shin, Yoon Kyung and Kim, Nae Ry and Kim, Se Ik and Lee, Yoo-Young and Park, Jeong-Yeol and Kim, Jae-Weon and Cho, Hyun-Woong and Lee, Jung-Yun},
title = {Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapy},
journal = {Journal of Gynecologic Oncology},
year = {2024},
doi = {10.3802/jgo.2024.35.e73}
}
EUVIMED